Halozyme Therapeutics
HALO
110.79
+1.07
+0.98%
Halozyme Therapeutics
US · HALO
#1276 by market cap
Listed 1970
110.79
+1.07
+0.98%
Live - 5344 symbols - heartbeat 37s ago
· 2026-10-08 07:31
Pre-market
111.00
+0.19%
After-hours
110.79
0.00%
Overnight
110.00
-0.71%
- Market cap
- 12.57B
- P/E (TTM)i
- 32.49
- P/Bi
- 87.58
- EPSi
- 2.56
- Div yieldi
- 0.00%
- 52W posi
- 89%
Reader sentiment
Are you bullish or bearish on HALO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.3 percentage points.
Institutional ownership
- Held by institutions
- 110.83% +0.28pp
- Institutions
- 800 -5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund87.23%
Public Company8.99%
Hedge Fund7.17%
Government Pension Fund2.66%
Private Company2.59%
Sovereign Wealth Fund1.31%
Individual/Insider1.06%
Family Office/Trust0.48%
Insurance Company0.25%
Top holders as of 2026-06-30
BlackRock
11.69% · 13.27M sh
Vanguard Capital Management, LLC
5.39% · 6.12M sh
Vanguard Portfolio Management, LLC
4.67% · 5.30M sh
State Street Global Advisors
4.56% · 5.18M sh
Boston Partners Global Investors, Inc.
2.44% · 2.77M sh
Invesco Ltd.
2.31% · 2.62M sh
William Blair Investment Management, LLC
2.27% · 2.57M sh
Geode Capital Management, LLC
2.22% · 2.52M sh
Snyder Capital Management, L.P.
2.11% · 2.40M sh
Morgan Stanley
1.98% · 2.24M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Helen Torley | Chief Executive Officer | 0.68% |
| Michael LaBarre | Senior VP & Chief Technical Officer | 0.15% |
| Matthew Posard | Independent Director | 0.05% |
| Mark Snyder | Chief Legal Officer | 0.04% |
| Nicole LaBrosse | Senior Vice President | 0.03% |
| Bernadette Connaughton | Independent Director | 0.03% |
| Jeffrey Henderson | Independent Chairperson | 0.03% |
| Akiko Moni Miyashita | Independent Director | 0.02% |
| Barbara Duncan | Independent Director | 0.01% |
| Mahesh Krishnan | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | James Daly | Independent Director | Other Acquisition | +1,169 | -- |
| 2026-09-30 | James Daly | Independent Director | Other Derivative Acquisition | +1,775 | $106.94 |
| 2026-09-30 | Matthew Posard | Independent Director | Automatic Disposition | -5,230 | $107.17–110.04 |
| 2026-09-15 | Matthew Posard | Independent Director | Automatic Disposition | -18,996 | $106.13–108.99 |
| 2026-09-10 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -60,000 | $18.41–108.67 |
| 2026-08-31 | Dannielle Appelhans | Director | Other Acquisition | +1,161 | -- |
| 2026-08-31 | Dannielle Appelhans | Director | Other Derivative Acquisition | +1,778 | $107.72 |
| 2026-08-18 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -60,000 | $18.41–107.77 |
| 2026-08-09 | Bernadette Connaughton | Independent Director | Automatic Disposition | -1,626 | $102.80 |
| 2026-07-07 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -1,923 | $12.07–80.19 |
| 2026-06-30 | David Ramsay | Former Chief Financial Officer | Other Derivative Acquisition | +16,232 | -- |
| 2026-06-30 | David Ramsay | Former Chief Financial Officer | Other Derivative Acquisition | +39,823 | $77.01 |
| 2026-06-30 | Bernadette Connaughton | Independent Director | Automatic Disposition | -1,625 | $76.40–77.21 |
| 2026-06-30 | Darren Snellgrove | Chief Financial Officer | Other Derivative Acquisition | +41,554 | -- |
| 2026-06-30 | Darren Snellgrove | Chief Financial Officer | Other Derivative Acquisition | +127,432 | $77.01 |
| 2026-06-29 | David Ramsay | Former Chief Financial Officer | Derivative Exercise and Sale | -5,408 | $78.27 |
| 2026-06-29 | David Ramsay | Former Chief Financial Officer | Derivative Exercise and Retained | +4,592 | -- |
| 2026-06-28 | Mahesh Krishnan | Independent Director | Derivative Exercise and Sale | -7,304 | $38.46–75.00 |
| 2026-06-11 | Mark Snyder | Chief Legal Officer | Derivative Exercise and Sale | -2,715 | $69.50 |
| 2026-06-11 | Mark Snyder | Chief Legal Officer | Derivative Exercise and Retained | +2,319 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:31:01 · For reference only, not investment advice and not tailored to your situation.